Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (51)

2022

  1. Enantioselective Synthesis and Pharmacological Evaluation of Aza‐CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

    Antioxidants, Vol. 11, Núm. 1

  2. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease

    Antioxidants, Vol. 11, Núm. 2

  3. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches

    Handbook of Experimental Pharmacology (Springer Science and Business Media Deutschland GmbH), pp. 229-259

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties

    Drug Development Research, Vol. 81, Núm. 3, pp. 283-294

  3. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

  4. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases

    Biomolecules, Vol. 10, Núm. 6

  5. New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10

    Cellular Physiology and Biochemistry, Vol. 54, Núm. 1, pp. 142-159

  6. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

  7. When it comes to an end: Oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration

    Antioxidants, Vol. 9, Núm. 8, pp. 1-34

2019

  1. Nrf2 plays a protective role against intravascular hemolysis-mediated acute kidney injury

    Frontiers in Pharmacology, Vol. 10

  2. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux

    Journal of Pineal Research, Vol. 67, Núm. 1

  3. The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation

    Aging Cell, Vol. 18, Núm. 3

2018

  1. The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca 2+ dysregulation, and mitochondrial abnormalities

    Journal of Neurochemistry, Vol. 145, Núm. 2, pp. 170-182

  2. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species

    Translational Research, Vol. 200, pp. 1-17

  3. Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

    Pharmacological Reviews, Vol. 70, Núm. 2, pp. 348-383

2017

  1. ConBr, A Lectin Purified from the Seeds of Canavalia brasiliensis, Protects Against Ischemia in Organotypic Culture of Rat Hippocampus: Potential Implication of Voltage-Gated Calcium Channels

    Neurochemical Research, Vol. 42, Núm. 2, pp. 347-359

  2. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7

  3. Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia

    European Journal of Medicinal Chemistry, Vol. 130, pp. 60-72